Developments in dementia treatments
This briefing focuses on two disease-modifying dementia drugs that are currently being appraised by the National Institute for Health and Care Excellence (NICE): lecanemab and donanemab

This note provides an overview of the health provisions in the Care Bill, including developments during the Bill’s Committee and Report Stages in the Lords.
Lords stages of the Care Bill: Health Provisions (87 KB , PDF)
The Care Bill was introduced into the House of Lords in May 2013. It aims to bring together existing care and support legislation and reform the social care system. It also includes reforms to the regulation of health services and care standards, and establishes Health Education England (HEE) and the Health Research Authority (HRA) as statutory non-departmental public bodies.
This note provides an overview of the health provisions in Parts 2 and 3 of the Bill, including developments during the Bill’s Committee and Report Stages in the Lords. It is not intended to be exhaustive, but rather to provide a summary of the most important amendments made.
The clauses in Part 2 of the Bill make provision to reform quality and safety regulation for care providers, providing the Government’s legislative response to the Francis Inquiry into the failings at Mid-Staffordshire Foundation Trust. This includes the introduction of “Ofsted-style rating” for hospitals and care homes, creating a single regime to deal with financial and care failures at NHS hospitals, introducing a duty of candour and making it a criminal offence for care providers to give false and misleading information about their performance.
Provisions in Part 3 of the Bill are intended to strengthen the independence of Health Education England (HEE) and the Health Research Authority (HRA), the bodies recently created to lead national systems for the education and training of health care professionals and to oversee health and social care research.
Lords stages of the Care Bill: Health Provisions (87 KB , PDF)
This briefing focuses on two disease-modifying dementia drugs that are currently being appraised by the National Institute for Health and Care Excellence (NICE): lecanemab and donanemab
A debate on children's health is scheduled to take place in the House of Commons Chamber on Thursday 10 July 2025. The subject for the debate was determined by the Backbench Business Committee, and the debate will be led by Dr Simon Opher MP.
NHS England funding allocations distributed to Integrated Care Boards (ICBs) in 2024/25.